ArticleFrontiers in psychiatry2026
A prospective observational cohort study: neurotoxic processes associated with psychiatric symptoms in heroin use disorder: the kynurenine pathway and neopterin levels.
Article in Frontiers in psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: This study investigated the effects of tryptophan (TRP) metabolism, kynurenine pathway (KP) and neopterin levels in heroin use disorder (HUD) in relation to neurotoxicity, treatment processes and psychiatric recovery. Method: The study groups consisted of patients with HUD who sought treatment at the hospital and received treatment, and a healthy control (C) group. The levels of neopterin, tryptophan and kynurenine in the participants' serum were determined, and the pre- and post-treatment results in the groups were compared with the controls. Results: Neopterin levels, reflecting immune system activation, were observed to decrease in HUD group after treatment (p = 0.021). Similarly, a decrease in levels of tumor necrosis factor-alpha (TNF-α), a pro-inflammatory cytokine, was also detected after treatment (p < 0.05). However, changes in interleukin-6 (IL-6) and interferon-gamma (IFN-γ) levels were not found to be significant (p > 0.05). The total scores of the Addiction Profile Index (API-K), which measures the severity of addiction, decreased significantly after treatment (p < 0.001). At the same time, improvement was observed in the general symptom level (GSI) and all subscales (including depression, anxiety, obsessive-compulsive disorders, and somatization) of the Symptom Checklist-90-Revised (SCL-90-R) scale, which assesses general psychopathology. Regression analyses revealed that the two strongest factors negatively affecting treatment success in the HUD group were duration of use (p = 0.028) and high neopterin levels (p = 0.020). Conclusion: This study highlights the critical role of immunological and neuroinflammatory processes in the success of HUD treatment. The findings indicate that biochemical recovery progresses in parallel with psychiatric recovery during treatment, and that changes in the KYN/TRP ratio and IL-6 levels have strong diagnostic and prognostic value. Neopterin, kynurenine, and tryptophan, on the other hand, have moderate prognostic value.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.